CClinicalTrials.gg
WithdrawnNCT00751283Updated Aug 14, 2013

Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

A Phase 2/3 interventional study of GRST Peripheral Catheter System in Peripheral Vascular Disease, sponsored by Vessix Vascular, Inc. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-14.

Sponsored by Vessix Vascular, Inc · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
Data was inconclusive
Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.

02

Conditions studied

03

In context

Vascular Diseases

1,027 studies on the registry are indexed under Vascular Diseases; 167 are open to participants now.

Browse Vascular Diseases studies →

Lead sponsor

Vessix Vascular, Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient is ≥18 years of age
  • Patient is Rutherford category 2-4
  • De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50%
  • Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of \<99%
  • Target lesion stenosis has a length of ≤100 mm based on visual assessment
  • Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment
  • Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot
  • Patient is willing and able to provide written informed consent prior to any study specific procedure
  • Patient is willing and able to comply with specified follow-up evaluations at the specified times

Exclusion criteria

Exclusion Criteria:

  • Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area
  • Evidence of thrombus in the target vessel
  • Prior ipsilateral or contralateral lower limb arterial bypass
  • Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure
  • Target lesion is severely calcified
  • Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
  • Any planned surgery within 30 days of the study procedure.
  • Renal failure (serum creatinine > 2.0 mg/dL)
  • Female with childbearing potential without a negative pregnancy test
  • Patient has had an organ transplant
  • Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study
  • In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    GRST Peripheral Catheter System

    Device: GRST Peripheral Catheter System

Interventions

  • DeviceGRST Peripheral Catheter System

    Treatment to dilate stenoses and reduce plaque in treated vessels

06

What researchers measure

Primary outcomes

  1. Major adverse clinical events rate

    Time frame: Up to 30 days

Secondary outcomes

  1. Binary restenosis

    Time frame: 30 days, 3 months, 6 months

  2. Target lesion revascularization

    Time frame: 30 days, 3 months, 6 months

  3. Amputation rate

    Time frame: 30 days, 3 months, 6 months

  4. Technical success

    Time frame: Treatment

  5. Serious adverse events rate, including major adverse clinical events

    Time frame: 30 days, 3 months, 6 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00751283
Lead sponsor
Vessix Vascular, Inc
Responsible party
Sponsor
First posted
Sep 11, 2008
Start date
Aug 2007
Primary completion
Nov 2010
Completion
May 2011
Last update
Aug 14, 2013

Study contacts

Dierk Scheinert, MD
principal investigator · Universität Leipzig Herzzentrum

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion